Dr. Yehuda Handelsman is the medical director and principal investigator of the Metabolic Institute of America and an endocrinologist in solo private practice in Tarzana, California, where he developed and successfully utilizes a comprehensive, multiple interventional approach to preventing and managing diabetes, obesity, lipid disorders and cardiovascular disease. A fellow of the American Association of Clinical Endocrinologists, American College of Physicians and National Lipid Association, he has been listed repeatedly in “Top Doctors of Los Angeles," “Southern California Super Doctors” and “Best Doctors of America”.
Dr. Handelsman is Immediate Past President of the American College of Endocrinology (ACE) and Past President of the American Association of Clinical Endocrinologists (AACE), Chair of the AACE Diabetes and Lipid Scientific Committees and a member of the Obesity Scientific Committee. He is Chair and Program Director of the annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, Chair and Founder of the International Committee for Insulin Resistance and the International Lipid Forum, senior scientific consultant for the Metabolic Endocrine Education Foundation and Treasurer of the Pacific Lipid Association.
A nationally and internationally recognized expert, Handelsman has researched, lectured and published extensively on diabetes, its comprehensive treatment and complications; the prevention of kidney disease and cardiovascular disease; controlling obesity; lipid disorders; hypertension; insulin resistance; PCOS; prediabetes; and cardio-metabolic disorders. He has also consulted and lectured on multi-hormonal obesity, diabetes an cancer, whole body glucose homeostasis, lipodystrophy, thyroid disease and osteoporosis. His book “Clinical Management of Cardiovascular Risk in Diabetes and Obesity” was published in 2016 by Professional Communications, Inc.
He is an associate editor of the Journal of Diabetes, member of the editorial panel of “European Medical Journal - Diabetes”, Editorial Advisory Board member for “Clinical Endocrinology News," is on the Editorial Board for “Endocrine Today” and the editorial advisory panel of “Treatment Strategies – Diabetes” of the Cambridge Research Center, United Kingdom. Dr. Handelsman frequently serves as guest editor and reviewer for multiple publications, such as the Journal of Clinical Hypertension, Metabolic Syndrome and Related Disorders, Postgraduate Medicine, Endocrine Practice, and Diabetes Care among others. He is the chair of the AACE 2011-2015 Comprehensive Diabetes Guidelines, a member of the AACE 2015-2016 Comprehensive Diabetes Algorithm and the 2012 and 2016 AACE Lipid and CVD prevention guidelines. He has been chair, member, co-author, and reviewer of many of AACE/ACE guidelines, consensuses and position statements on obesity, glucose monitors, continuous glucose monitors and hypertension. He has chaired special scientific consensus efforts, including Insulin Resistance, Diabetes and Cancer, Clinical Approach toLlipodystrophy and SGLT2 inhibitors and DKA.
Dr. Handelsman is a member of the American College of Endocrinology, American Diabetes Association, National Osteoporosis Foundation, American Thyroid Association, Academy of Thyroidologists, American College of Physicians, Los Angeles and California Medical Associations and the American Medical Association, as well as the National Lipid Association.
He is a Summa Cum Laude graduate of the University of the Pacific in Stockton, California. He is a Fellow of the American College of Endocrinology, the American College of Physicians and the National Lipid Association. Dr. Handelsman earned his doctor of medicine degree from Tel Aviv University Sackler Faculty of Medicine in Israel. He completed a subsequent internship and residency in internal medicine at New York Infirmary Beekman Downtown Hospital under the supervision of New York University. His fellowship in diabetes and endocrinology was conducted at the University of Southern California Medical School in Los Angeles.